Amylyx Pharmaceuticals, Inc.
AMLX
Rang in Aktien
#4292
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical... Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Aktienkurs
$29.32
Zuletzt synchronisiert: 2026-10-21
Marktkapitalisierung
$3.68B
Veränderung (1 Tag)
1.91%
Veränderung (1 Jahr)
97.84%
Land
US
Handel Amylyx Pharmaceuticals, Inc. (AMLX)
Kategorie
Healthcare
Kursverlauf für Amylyx Pharmaceuticals, Inc. (AMLX)
Höchster Schlusskurs: $27.68 am 2026-10-01
Niedrigster Schlusskurs: $19.75 am 2022-01-01
Niedrigster Schlusskurs: $19.75 am 2022-01-01
Kursverlauf der Aktie von Amylyx Pharmaceuticals, Inc. von 2022 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | 41.29% |
| 2025 | 192.53% |
| 2024 | -69.40% |
| 2023 | -60.37% |
| 2022 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.10 | -4.29% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
